Open access
Open access
Powered by Google Translator Translator

Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease.

6 Sep, 2022 | 14:22h | UTC

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Respiratory Medicine

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.